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Demyelinating optic neuritis is the most common cause of unilateral painful visual 
loss in the United States. Although patients presenting with demyelinating optic 
neuritis have favorable long-term visual prognosis, optic neuritis is the initial clinical 
manifestation of multiple sclerosis in 20% of patients. The Optic Neuritis Treatment 
Trial (ONTT) has helped stratify the risk of developing multiple sclerosis after the 
first episode of optic neuritis based on abnormal findings on brain MRI. The ONTT 
also demonstrated that while initial treatment of optic neuritis with intravenous 
corticosteroids followed by an oral taper accelerates visual recovery, its use does not 
improve long-term visual outcomes. Long-term treatment with immunomodulating 
agents such as interferons has been shown to improve clinical outcomes and 
neuroimaging abnormalities in multiple sclerosis; furthermore interferon use has 
been associated with decreased risk of subsequent multiple sclerosis in patients 
with an acute neurologic syndrome. However, several questions regarding the 
presentation, management, and implications of acute demyelinating optic neuritis 
remain unanswered.
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INTRODuCTION
A variety of conditions lead to inflammation 
of the optic nerve (optic neuritis), however, 
the form associated with demyelination 
due to multiple sclerosis is most common.20 
Demyelinating optic neuritis is not only the 
most common cause of unilateral painful visual 
loss in the United States and many other parts 
of the world1, but is also a diagnosis that brings 
very concerning news to an often previously 
healthy patient. Optic neuritis is the first clinical 
manifestation of multiple sclerosis in 20% of 
patients.1 Patients with optic neuritis will 
likely have many questions for the diagnosing 
physician, whether that be an ophthalmologist, 
a neurologist, or a primary care physician. It 
is important that these practitioners have a 
clear understanding of the condition, how to 
make the diagnosis, its treatment, and perhaps 
most importantly, its implications for future 
management.
PATHOGENESIS
The pathogenesis of optic neuritis, as with 
other demyelinating events associated with 
multiple sclerosis, is not entirely understood. It 
is believed that some inflammatory process leads 
to peripheral T-cell activation. These T-cells 
are thought to cross the blood-brain barrier 
and cause a delayed type IV hypersensitivity Optic Neuritis; Dooley and Foroozan
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reaction causing destruction of myelin, the 
insulator and protector of nerves.1 It was 
previously thought that this process only affects 
myelin and is limited to the white matter. More 
recent technology, including optical coherence 
tomography, suggests that the axon of the 
nerve itself is affected and that the gray matter 
is also involved.2 Clinically, inflammation of 
the optic nerve translates to visual loss, which 
is typically followed by visual recovery. This 
recovery often begins spontaneously, within 
two to three weeks, and stabilizes over several 
months.3
CLINICAL FINDINGS
The typical patient who develops acute 
demyelinating optic neuritis is an otherwise 
healthy young adult, most often 20 to 45 
years of age; women are affected three times 
more commonly than men.4 Children may 
also develop optic neuritis, but in such cases 
it is typically related to an infection, often 
viral, is usually bilateral5, and will not be 
discussed here. Visual loss, periocular pain 
and dyschromatopsia make up the three most 
common symptoms, however not all patients 
present with all three complaints. The visual 
loss is commonly unilateral, varies in severity 
from mild to severe, with total loss of light 
perception, and progresses for an average of 
seven to ten days. Ninety percent of patients 
with optic neuritis have periocular pain, which 
may occur before the onset of vision loss.1 
However, patients may not initially complain 
of pain. It is helpful to specifically ask if there 
is pain with eye movements, which is thought 
to occur as the inflamed optic nerve is stretched 
with globe motion. Color and contrast sensitivity 
are often decreased out of proportion to loss 
of visual acuity.6 Visual field loss, especially 
a central scotoma, is typical in optic neuritis.7
A relative afferent pupillary defect is present 
in the affected eye unless there is symmetric 
involvement or history of optic neuropathy in 
the fellow eye.6 Sixty-five percent of patients 
have normal optic nerve appearance on 
funduscopic examination at presentation; these 
patients are considered to have retrobulbar 
optic neuritis.1 The optic disc may be swollen, 
but prominent swelling of the nerve head, the 
presence of exudates, or marked hemorrhage 
may suggest other diagnoses.4 Optic disc pallor 
typically develops four to six weeks after the 
onset of inflammation.
Several other findings have been described 
in optic neuritis, though they are not sensitive 
indicators of the condition. These include 
Uhthoff’s phenomenon which describes 
worsening of vision with increased body 
temperature, and the Pulfrich phenomenon, in 
which a simple pendulum swinging in one plane 
appears to trace an ellipse due to asymmetrical 
optic nerve conduction velocity.1
Distinguishing Features from Other Optic 
Neuropathies
Since the diagnosis of optic neuritis is clinical, 
it is useful for physicians to understand other 
processes which cause similar findings. The 
differential diagnosis for optic neuritis (defined 
as optic nerve inflammation) is very broad, 
including other auto-immune neuropathies (e.g., 
systemic lupus erythematosus), rheumatologic 
conditions, inflammatory conditions (e.g., 
sarcoidosis), compressive neuropathies (e.g., 
meningioma), infections (e.g., sinusitis), 
and toxic (e.g., ethambutol) or nutritional 
neuropathies.
Two conditions which are thought to be 
non-inflammatory and most closely resemble 
the clinical profile of optic neuritis are anterior 
ischemic optic neuropathy (AION) and Leber 
hereditary optic neuropathy (LHON). While 
sudden unilateral visual loss with optic disc 
swelling is present in AION, the patients are 
typically over 50 years of age (without a female 
preponderance) and less commonly have pain 
with eye movement.21 By definition, the optic 
disc must be swollen acutely in AION, and the 
swelling is often segmental with hemorrhage.7 
LHON, like optic neuritis, may cause visual 
field loss with a central scotoma, impaired 
visual acuity and poor color vision. However, it 
occurs most commonly in young men (eighty-
five percent of the time), is not typically 
accompanied by pain and usually progresses Optic Neuritis; Dooley and Foroozan
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over weeks to months to involve both eyes 
sequentially.4 Because of the mitochondrial 
inheritance pattern, there is often a family 
history of subacute visual loss in maternally 
related men. Fat suppressed orbital magnetic 
resonance imaging (MRI) typically shows 
enhancement of the optic nerve in optic neuritis 
(Fig. 1), but not so in AION or LHON.
Brain MRI
Because of the known association between 
optic neuritis and multiple sclerosis, patients 
without a known history of multiple sclerosis 
are typically offered a brain MRI. The Optic 
Neuritis Treatment Trial is one study that has 
helped stratify the risk of developing multiple 
sclerosis on the basis of abnormal findings on 
brain MRI (Fig. 2). A patient with a first episode 
of optic neuritis but normal brain MRI has a 
25% chance of developing multiple sclerosis 
at fifteen years, as opposed to a 72% risk for 
patients with one or more lesions (Fig. 3).8 Other 
studies have shown that more detailed early 
MRI findings such as baseline lesion number, 
location, and activity; three-month lesion activity 
measures; and brain atrophy, magnetization 
Figure 1. Coronal T1 contrast-enhanced fat suppressed 
magnetic  resonance  imaging  showing  enhancement 
of the left optic nerve (arrow) which is typical of optic 
neuritis.
Figure 3. Life-table analysis of multiple sclerosis (MS) 
according  to  the  number  of  lesions  on  baseline  brain 
magnetic resonance imaging (MRI). Life-table intervals 
are defined by annual examinations during the first 5 
years of the study and periods after the 5- and through 
the 10-year examinations and after the 10- and through 
the 15-year examinations. The table under the horizontal 
axis represents the number of patients during follow-up 
who had not developed MS at the end of the previous 
interval.  Patients  with  1  or  2  lesions  on  MRI  were 
combined into a single group because the rates of MS 
were similar. From “Multiple sclerosis risk after optic 
neuritis:  final  optic  neuritis  treatment  trial  follow-up. 
Arch Neurol 2008;65:727-732.”8
Figure 2.  Axial  magnetic  resonance  imaging  fluid-
attenuated  inversion  recovery  (FLAIR)  sequence 
demonstrates  periventricular  lesions  typical  of 
demyelination from multiple sclerosis.Optic Neuritis; Dooley and Foroozan
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transfer ratio, and spectroscopy measures 
may improve the prediction of development 
of multiple sclerosis. New T2 lesions on an 
early follow-up scan have been suggested as 
the strongest independent predictor of multiple 
sclerosis.9 Although additional predictions can 
be made based on gender, race, age, family 
history, and location of the swelling along the 
optic nerve, the number of lesions on initial 
brain MRI is most strongly related to the risk 
of developing multiple sclerosis.1,8
Other Tests
Other diagnostic tests do not have such clear 
support. Lumbar puncture for cerebrospinal fluid 
(CSF) analysis, for example, is recommended 
by some to look for the oligoclonal banding 
typical of multiple sclerosis.22 Others have noted 
that patients with oligoclonal CSF bands are 
typically the same patients with an abnormal 
MRI, and that lumbar puncture should be 
reserved for patients in whom the diagnosis 
of optic neuritis is in question.10 Visual evoked 
potentials (VEPs), including multifocal VEPs, are 
recommended by some authors as a sensitive 
and specific tool for detecting demyelinating 
optic neuritis,11 while others report the test 
not to be helpful in differentiating the cause of 
optic neuropathy in its acute phase, reserving 
the test for subclinical cases in which poor color 
vision or a pale optic disc are noted.1 Other 
tests, such as optical coherence tomography, 
may be useful in documenting thinning of 
the retinal nerve fiber layer after an episode 
of optic neuritis (Figures 4, 5), and its clinical 
utility is expanding.12
(A) (B)
Figure 4. A 45 year-old man with prior optic neuritis in the right eye. The right optic disc (A) is pale compared to the 
normal left optic disc (B).
Figure 5. Optical coherence tomography shows thinning 
of the retinal nerve fiber layer of the right eye in the same 
patient as in Fig. 4.Optic Neuritis; Dooley and Foroozan
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MANAGEMENT
Optic Neuritis Treatment Trial
Once a diagnosis of optic neuritis has been 
made and the risk of future development of 
multiple sclerosis has been estimated on the 
basis of a brain MRI, patients will likely ask 
about treatment options. The largest study 
to address this question is the Optic Neuritis 
Treatment Trial, a multicenter randomized 
clinical trial with fifteen years of follow up. 
Patients were assigned to three groups: one 
received oral prednisone, another received 
intravenous methylprednisolone followed by 
an oral prednisone taper, and the last received 
oral placebo.
The  trial  showed  that  intravenous 
corticosteroids followed by an oral taper 
accelerated visual recovery, but did not 
improve the long-term visual outcome when 
compared to placebo. Patients who were 
treated with oral corticosteroids alone did 
not have improved visual outcomes and were 
actually shown to have an increased rate of 
recurrent optic neuritis in the same or fellow 
eye.3 Thus viable options for treatment of an 
initial bout of optic neuritis include either 
treatment with intravenous corticosteroids 
followed by an oral steroid taper, or no 
treatment at all. Oral corticosteroids alone 
at doses of 1 mg/kg do not have a beneficial 
role. Interestingly, the treatment of other 
clinical presentations and exacerbations of 
multiple sclerosis is based on this data even 
if the exacerbation does not involve vision. 
This is likely not only because optic neuritis 
is such a common finding in patients with 
multiple sclerosis, but also because it is the 
most consistent and thoroughly defined event 
associated with the disease.
Long-Term Management
The presentation of demyelinating optic neuritis 
often invites referral to a neurologist familiar 
with the diagnosis and treatment options. Data 
from the Optic Neuritis Treatment Trial have 
shown that patients who present with acute 
demyelinating optic neuritis have a favorable 
long-term visual prognosis, even if they develop 
multiple sclerosis.13
Long-term treatments for optic neuritis 
include the interferons, often used in patients 
with multiple sclerosis. The neurologic 
literature has shown that patients treated 
with  immunomodulating  agents  have 
improved clinical outcomes and neuroimaging 
abnormalities compared to those who are not 
treated.14,15 Furthermore, use of interferons 
has been associated with a lower risk of 
subsequent multiple sclerosis in patients with 
an acute neurologic syndrome, including 
optic neuritis.16
unanswered Questions
Several  unanswered  questions  remain 
regarding the presentation, treatment, and 
implications of optic neuritis. Studies have 
shown that the risk of developing clinically 
definite multiple sclerosis after presenting 
with a clinically isolated syndrome such 
as optic neuritis is increased in patients 
with an abnormal brain MRI, and evidence 
supports treatment of these patients with 
immunomodulating agents.14-16 Patients with 
a normal brain MRI still have a 15-22% risk 
of developing multiple sclerosis, but as the 
management of a patient with a first episode 
of optic neuritis and a normal brain MRI 
has not been studied extensively, it remains 
controversial.17-19 Furthermore, while the 
treatment of acute demyelinating optic neuritis 
with intravenous corticosteroids followed by 
an oral corticosteroid taper is supported by 
evidence from the Optic Neuritis Treatment 
Trial,3 the role of high dose oral corticosteroids 
in optic neuritis has not been systematically 
studied. The value of corticosteroids in 
patients with recurrent optic neuritis is also 
undetermined at this time.
Large clinical trials with long-term follow-
up have provided invaluable insights on the 
clinical manifestations, management, prognosis, 
and implications of an initial bout of acute 
demyelinating optic neuritis, but the remaining 
uncertainties highlight the need for continued 
research.Optic Neuritis; Dooley and Foroozan
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